{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002496","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.580841+00:00","generated_at":"2026-06-20T17:23:33.454068+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Armata closes $30M secured convertible credit from Innoviva at 8%, due Jan 2024","bullets":["Gross proceeds $30M from Innoviva Strategic Opportunities LLC, Armata's largest shareholder, at 8% interest, matures Jan 10, 2024.","Loan converts to common stock upon qualified financing at 15% discount to investors' price; lender option to convert after SEC registration effective at greater of book value or $1.52/share.","Proceeds used to fund clinical development of AP-PA02 and AP-SA02 and complete cGMP manufacturing facility.","Loan secured by substantially all assets of Armata and its domestic/foreign material subsidiaries; no warrants issued."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002496","json":"https://secwatch.observer/filing/0001104659-23-002496.json","markdown":"https://secwatch.observer/filing/0001104659-23-002496.md","text":"https://secwatch.observer/filing/0001104659-23-002496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/0001104659-23-002496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/tm232848d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:23:33.454068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e4795e83b2b4a8c9ddfafce4448d2012de2e2dc","claim":"Armata Pharmaceuticals, Inc. incurred term loan of $30 million with Innoviva Strategic Opportunities LLC at 8.0% per annum maturing January 10, 2024.","evidence_excerpt":"The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30 million (the “Loan”) at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/0001104659-23-002496-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$30 million"},{"label":"Counterparty","value":"Innoviva Strategic Opportunities LLC"},{"label":"Rate","value":"8.0% per annum"},{"label":"Maturity","value":"January 10, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ba506b577463aa5319b2b70441f854c7b683ce5c","claim":"Armata Pharmaceuticals, Inc. entered into Credit Agreement with Innoviva Strategic Opportunities LLC valued at $30 million (effective 2023-01-10).","evidence_excerpt":"On January 10, 2023, Armata Pharmaceuticals, Inc. (the “Company”) entered into, as borrower, a secured convertible credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/0001104659-23-002496-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Innoviva Strategic Opportunities LLC"},{"label":"Value","value":"$30 million"},{"label":"Effective","value":"2023-01-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}